ASH 2021

Addition of Ibrutinib to Chemoimmunotherapy in CLL

The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...

Read More

Persistent disparities in ALL health outcomes

Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukemia (ALL). Differences in leukemia biology or disease prognosticators do...

Read More
  • 1
  • 2

For latest news and updates
Email-id is invalid